Meanwhile, MSC‐EXO suppressed diabetes‐associated upregulation of Atrogin1 and MuRF1 protein levels, promoted phosphorylation of AMPK(T172) and ULK1(S555), and reduced LC3II/LC3I and p62 content (Figures7E and S8G) and the proportion of LC3‐positive muscle fibres (Figures7F and S8H). Here, MAP1LC3A is linked to diabetes mellitus.